Carlyle, GTCR Eye Sale of Curia's Spanish Pharma Assets

The Carlyle Group and GTCR are reportedly exploring the divestiture of Curia's pharmaceutical operations based in Spain, engaging the advisory services of Rothschild to manage the process. This strategic review signals a potential shift in the ownership of key European manufacturing and development capabilities within the contract development and manufacturing organization (CDMO) sector.

The Spanish assets under consideration include the Gadea Pharmaceutical Group facility located in Valladolid. This site was integrated into Curia's network following its acquisition, aimed at enhancing the company's capacity for both branded and generic pharmaceutical development and manufacturing, alongside expanding its active pharmaceutical ingredient (API) portfolio. The facility represents a significant piece of Curia's European footprint.

Curia, formerly known as AMRI, was taken private by Carlyle and GTCR in 2017 through a transaction valued at approximately $1.5 billion. Since then, the company has significantly expanded its global reach, establishing a presence across the United States, Europe, and Asia. Curia offers a comprehensive suite of services that span the entire drug lifecycle, from initial discovery research to large-scale commercial manufacturing, positioning itself as a key player in the pharmaceutical outsourcing market.

This potential sale aligns with a broader trend of portfolio optimization observed among private equity-backed entities in the pharmaceutical services industry. The CDMO market, particularly in Europe, has seen robust interest from potential acquirers. This heightened demand is driven by pharmaceutical companies' increasing reliance on external partners for critical manufacturing and development functions, a trend accelerated by supply chain complexities and the need for specialized expertise.

The selection of Rothschild, a prominent independent advisory firm, underscores the seriousness of the evaluation. Rothschild is tasked with assessing various strategic alternatives, which could include a sale to a strategic industry player or another financial sponsor. The Spanish operations are anticipated to draw attention from both pharmaceutical firms looking to bolster their manufacturing capacity and investment funds seeking to capitalize on the dynamic growth within the CDMO sector.

The global CDMO market is projected to experience substantial growth, with various reports estimating a compound annual growth rate (CAGR) in the high single digits or even low double digits over the next five to seven years. This expansion is fueled by factors such as increasing drug development pipelines, the rise of biologics and complex therapies requiring specialized manufacturing, and the ongoing trend of outsourcing by pharmaceutical giants. The Spanish assets, therefore, represent a valuable opportunity within this expanding market.